StockNews.AI
ACAD
StockNews.AI
167 days

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

1. Acadia Pharmaceuticals reports promising DAFFODIL™ study results for DAYBUE® in young girls. 2. The drug shows similar safety profile in younger children as in older patients.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive study results may bolster investor confidence, similar to past successful trials, lifting stock price.

How important is it?

The study results provide critical validation for DAYBUE® and can influence market sentiment positively.

Why Short Term?

The results are recent and can lead to immediate market reactions and trade activity.

Related Companies

ACAD
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an.

Related News